Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Carnival prices upsized $3bn note offering

(Sharecast News) - Carnival priced an upsized $3bn offering of 5.75% senior unsecured notes due 2032 on Tuesday, with proceeds earmarked for debt repayment and refinancing, as part of its broader effort to streamline its capital structure and reduce secured borrowings. The FTSE 250 cruise operator said the proceeds would be used to fully repay borrowings under its senior secured term loan facility due in 2028.

Remaining net proceeds, alongside existing cash, would be used to redeem $2.4bn of 5.75% senior unsecured notes maturing in 2027.

A conditional notice of redemption for those 2027 notes had been issued, with a redemption date set for 17 July.

The redemption price included the full principal, an applicable make-whole premium, and accrued interest up to but excluding the redemption date.

Carnival said the offering was a continuation of its deleveraging strategy, noting that following the transaction, the firm's senior secured debt would fall to $3.1bn.

The company said that all of its remaining secured debt included provisions for the security to fall away upon achieving investment-grade ratings from at least two of the three major credit agencies.

It said the new notes would also be governed by investment grade-style covenants.

The unsecured notes would mature on 1 August 2032 and pay interest semi-annually at 5.75%, starting 1 February 2026.

They would be jointly and severally guaranteed on an unsecured basis by Carnival plc and certain subsidiaries.

Carnival said the offering, conducted via a private placing, was expected to close on 16 July, subject to customary conditions.

At 1027 BST, shares in Carnival were up 0.4% in London at 1,985p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.